Congenital Hyperinsulinism Treatment MarketSize and Trends

The global congenital hyperinsulinism treatment market is estimated to be valued at US$ 206.0 million in 2022 and is expected to exhibit a CAGR of 5.7% during the forecast period (2022-2030).

Figure 1. Global Congenital Hyperinsulinism Treatment Market Share (%), by Distribution Channel, 2022

Global Congenital Hyperinsulinism Treatment Market- Drivers

Growing awareness of congenital hyperinsulinism among the population is expected to drive the global congenital hyperinsulinism treatment global market. For instance, Congenital Hyperinsulinism International, a voluntary, non-profit organization focused on providing support such as disease diagnosis and disease management to the patient with CHI, and raising awareness among the people suffering from CHI. On 16 August 2022, the organization held a family conference where well renowned researchers, physicist, doctors, and patients of congenital hyperinsulinism with their family were featured. The conference were held to share the experience of patients and their family, to get the awareness about the disease and to know all the aspects of disease and its treatments.

Rise in research & development activities for the development of congenital hyperinsulinism drugs are expected to drive the market growth during the forecast period. For instance, in October 2021, Hanmi Pharm.Co., Ltd., a Pharmaceutical company initiated Phase 2 Clinical trial for HM15136 to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136, a Glucagon analog chemically conjugated with constant region of human immunoglobulin via non-peptidyl flexible linker, used as add-on therapy in subjects with CHI with persistent hypoglycemia and the trial is expected to be completed on March 2025.

Congenital Hyperinsulinism Treatment Market Report Coverage

Figure 2.Global Congenital Hyperinsulinism Treatment Market Share (%), by Region, 2022

Global Congenital Hyperinsulinism Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

Moreover, clinical trials of endocrinal disease therapies and treatments has negative effect of COVID-19. For instance, in September, 2020, an article was published by Nepal Journal of Epidemiology suggested that the COVID-19 pandemic had negative impact on the clinical trial activities of endocrinal diseases such as congenital hyperinsulinism. There was decrease in new patient/subject enrollment which was due to mitigation efforts such as self-isolation and inaccessibility of health care facilities during pandemic with all aspects of clinical trials at various levels. The observed decrease in new subject enrollment in clinical trials was 64% in March 2019 to march 2020, 91 % in April 2019 to April 2020, and 89% in May 2019 to May 2020.